Connect Biopharma Holdings Ltd (CNTB) Stock Analysis

AI analysis of Connect Biopharma Holdings Ltd (CNTB)

Sell

Connect Biopharma Holdings Ltd is not a good buy right now due to its current price of $0.7771, which is significantly below its 52-week high of $3.82, indicating a steep decline of approximately 80%. The RSI of 28.565 suggests the stock is oversold, but the overall financial performance shows a troubling trend with a net income loss of $17,284,000 in the latest quarter. Furthermore, the forward P/E ratio of 0.7669 indicates potential undervaluation, but the company has not yet proven consistent revenue generation, with a year-to-date change of -69.16%. The main risk is the substantial net margin loss of -624.42% in the latest quarter, which raises concerns about the company's sustainability and ability to recover.

Valuation Metrics

The current forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB) is 0.77, compared to its 5-year average forward P/E of -2.02.

Forward P/E

Overvalued

5Y Average P/E

-2.02

Current P/E

0.77

Overvalued

0.52

Undervalued

-4.56

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.02

Current EV/EBITDA

-0.04

Overvalued

0.66

Undervalued

-0.62

Forward P/S

Fair

5Y Average P/S

1966.31

Current P/S

0.49

Overvalued

10717.76

Undervalued

-6785.13

Alphio AI Price Scenarios for CNTB

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CNTB

$1.88

Scenario price

B

Base

Base · 50%CNTB

$1.56

Scenario price

B

Bear

Bear · 25%CNTB

$1.53

Scenario price

Whales holding CNTB

Q

Qiming Weichuang Venture Capital Management (Shanghai) Company Limited

+ HoldingCNTB

+0.00%

3M Return

CNTB FAQ — answered by Alphio AI

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Connect Biopharma Holdings Ltd is not a good buy right now due to its current price of $0.7771, which is significantly below its 52-week high of $3.82, indicating a steep decline of approximately 80%. The RSI of 28.565 suggests the stock is oversold, but the overall financial performance shows a troubling trend with a net income loss of $17,284,000 in the latest quarter. Furthermore, the forward P/E ratio of 0.7669 indicates potential undervaluation, but the company has not yet proven consistent revenue generation, with a year-to-date change of -69.16%. The main risk is the substantial net margin loss of -624.42% in the latest quarter, which raises concerns about the company's sustainability and ability to recover.